Skip to content

Replimune Group REPL Total Liabilities

Total Liabilities at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$9.45B+15.8%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$205M+38.3%
Immunome logo
ImmunomeIMNM
$31.11M-12.5%
CG Oncology logo
CG OncologyCGON
$43.48M+85.6%
Erasca, Inc. logo
Erasca, Inc.ERAS
$67.71M-5.6%
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's total liabilities?
Replimune Group (REPL) reported total liabilities of $123.05M in Q4 2025.
How has Replimune Group's total liabilities changed year-over-year?
Replimune Group's total liabilities increased by 1.5% year-over-year, from $121.25M to $123.05M.
What is the long-term trend for Replimune Group's total liabilities?
Over 4 years (2021 to 2025), Replimune Group's total liabilities has grown at a 32.2% compound annual growth rate (CAGR), from $44.37M to $135.49M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.